title: Can sorafenib cause hypothyroidism?
authors.forename: S I
authors.initials: SI
authors.lastname: Robinson
authors.forename: T J
authors.initials: TJ
authors.lastname: Hobday
authors.forename: A
authors.initials: A
authors.lastname: Sathananthan
authors.forename: J C
authors.initials: JC
authors.lastname: Morris
authors.forename: R R
authors.initials: RR
authors.lastname: McWilliams
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D018273:Carcinoma, Islet Cell / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D009536:Niacinamide / Q000031:analogs & derivatives; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000473:pathology; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib